Suchergebnisse - "Lommatzsch, Marek"

PubPharm (8)

1

Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab : The ProVENT Study

enthalten in: Respiration; international review of thoracic diseases | 2024

von Korn, S. | Schmidt, O. | Timmermann, H. | +8

2

Dupilumab treatment increases transitional B cells in severe asthma

enthalten in: Allergy | 2023

von Lommatzsch, M. | Dost, M. | Jaishankar, N. | +4

3

Eosinophilic pleural effusion and stroke with cutaneous vasculitis : Two cases of dupilumab-induced hypereosinophilia

enthalten in: Allergy | 2021

von Lommatzsch, M. | Stoll, P. | Winkler, J. | +4

4

Benralizumab strongly reduces blood basophils in severe eosinophilic asthma

enthalten in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | 2020

von Lommatzsch, M. | Marchewski, H. | Schwefel, G. | +3

5

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma : 1-year results from the BORA phase 3 extension trial

enthalten in: The Lancet. Respiratory medicine | 2019

von Busse, W. | Bleecker, E. | FitzGerald, J. | +107

CommentIn: Lancet Respir Med. 2019 Jan;7(1):5-6. - PMID 30416084

6

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA) : a randomised, double-blind, placebo-controlled phase 3 trial

enthalten in: Lancet (London, England) | 2016

von FitzGerald, J. | Bleecker, E. | Nair, P. | +12

CommentIn: Lancet. 2016 Oct 29;388(10056):2059-2060. - PMID 27609409

7

Treatment of refractory asthma with antibodies

enthalten in: Deutsche medizinische Wochenschrift (1946) | 2016

von Lommatzsch, M.

8

Against all odds : anti-IgE for intrinsic asthma?

enthalten in: Thorax | 2014

von Lommatzsch, M. | Korn, S. | Buhl, R. | +1

1
[1]